Huihe Medical Completes Hundreds of Millions USD Series D Financing, Advances Globalization of High-End Domestic Medical Devices

Recently, Shanghai Huihe Healthcare Technology Co., Ltd. (hereinafter referred to as "HuiHe Healthcare") announced the completion of its D-round financing. This is another significant milestone for HuiHe Healthcare since the completion of its C+ round financing in 2022, marking that the company's innovative strength in the field of interventional treatment for structural heart disease has gained high recognition from the capital market.

Shanghai Huihe Healthcare Technology Co., Ltd. was established in 2019. It is a high-tech enterprise focusing on the research, development, production, and commercialization of cardiovascular interventional medical devices, with its headquarters located in Songjiang District, Shanghai. Driven by the concepts of "clinician-engineering integration" and "original innovation," HuiHe Healthcare is committed to promoting China-produced high-end medical devices globally.

In recent years, insurance funds have become an important driving force for the development of the medical and health industry. As a typical representative of "patient capital," insurance funds possess unique advantages such as long-term stability, security, and cross-cycle allocation, which are highly compatible with the long-cycle and high-investment characteristics of the medical and health industry. Meanwhile, as the payer in the medical and health industry, insurance has a natural connection with innovative medical device companies. It is essential to reasonably build a complete health management ecosystem involving "clients + payers + demand side + resource providers" to achieve deep synergy between the core insurance business and the medical industry.

It is reported that there are significant unmet clinical needs in the field of structural heart disease. According to data from the *Chinese Journal of Circulation*, in 2023, the number of hospitals in China treating inpatients with structural heart disease increased by 32.5% compared to 2022, rising from 5,129 hospitals to 6,794 hospitals. The number of inpatient visits increased by 38.1%, from 3.39 million to 4.68 million people. The substantial gap between its high incidence rate and low intervention rate is increasingly drawing attention from the global cardiovascular community. The innovative products developed by HuiHe Healthcare have brought breakthrough solutions to this field.

HuiHe Healthcare has industry-leading advantages in delivery systems, precision manufacturing, simulation modeling, and automated production. It has multiple independently developed, world-leading commercial products in the field of cardiovascular interventions. Its globally pioneering core product, the K-Clip® Transcatheter Tricuspid Valve Repair System, replicates classic surgical procedures to repair tricuspid regurgitation through minimally invasive surgery. It received approval from the National Medical Products Administration (NMPA) for market launch in March 2025 and has since been applied on a large-scale commercial basis.